• / Free eNewsletters & Magazine
  • / My Account
Home>Stocks>Neurocrine Biosciences

Neurocrine Biosciences

  1. All
  2. Morningstar Articles
  3. 3rd Party
  1. Endometriosis - Global Strategic Business Report 2015-2022: Leading drugs are Depo Provera, Eligard, Lupron, Visanne & Zoladex - Research and Markets

    Endometriosis - Global Strategic Business Report 2015-2022: Leading drugs are Depo Provera, Eligard, Lupron, Visanne & Zoladex - Research and Markets

  2. CLS: Slow Down, Think Before You Trade

    On Monday, Neurocrine Biosciences NBIX accelerated its anticipated filing date for indiplon capsules to the second quarter of 2007 instead of 2009. We're placing Neurocrine under review while we revisit our assumptions, and because DOV Pharmaceutical DOVP is entitled to a royalty on any indiplon ...

Upcoming Events
Conferences
Webinars

©2014 Morningstar Advisor. All right reserved.